Skip to content

Study on spatio-temporal regulation mechanism of acupuncture intervention on central inflammatory network in stable COPD patients based on brain-gut axis

Study on spatio-temporal regulation mechanism of central inflammatory network in stable COPD patients with different acupuncture frequency

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2200006810
Enrollment
Unknown
Registered
2022-11-22
Start date
2022-11-30
Completion date
Unknown
Last updated
2023-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

chronic obstructive pulmonary disease

Interventions

control group:Conventional treatment
treatment group:acupuncture at acupoints
control group:acupuncture at nonacupoints

Sponsors

Hospital of Chengdu University of Traditional Chinese Medicine / Chengdu University of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
40 Years to 80 Years

Inclusion criteria

Inclusion criteria: (1) For patients diagnosed with COPD, the disease has been stable for at least the past 4 weeks without acute exacerbation; (2) 40 years old = age = 80 years old, gender is not limited; right-handed; (3) Patients with FEV1 between 25% and 80% after inhalation of bronchodilators; (4) The patient has at least one moderate or severe acute exacerbation in the past year; (5) According to the recommended medication regimen of GOLD, received stable western medicine treatment within 3 months before treatment; (6) No history of infection or aggravation of respiratory symptoms for at least the past 4 weeks, no drug changes within 3 months before the start of the study, and no symptoms of edema; (7) Montreal Cognitive Assessment Basic Edition (MoCA-B) low education group (=6 years) =20 points, middle school group (7-12 years) =23 points, university group (>12 years) =25 points; (8) Patients who have not undergone pulmonary rehabilitation in the past 6 months; (9) Good compliance, willing to cooperate with the research, and the patients signed the informed consent.

Exclusion criteria

Exclusion criteria: (1) Patients with severe cardiovascular and cerebrovascular, nervous system, blood system, immune system, digestive system diseases, chronic liver and kidney insufficiency, malignant tumors, and uncontrolled blood pressure and blood sugar; (2) Segmentectomy, wedge resection or lobectomy, pneumonectomy, or lung volume reduction surgery (including bronchoscopy lung volume reduction surgery) due to COPD; (3) Other concomitant active or clinically significant respiratory diseases that have a significant impact on the research: such as subjects with active pulmonary tuberculosis, bronchiectasis, pulmonary hypertension, pulmonary interstitial disease or other active pulmonary diseases; (4) Those who use long-term oxygen therapy (oxygen therapy time > 15h/d) or mechanical ventilation; (5) Those who have a history of mental illness, mental retardation, or inconvenience in movement, who could not be sedated and cooperated with the examination at that time; (6) Those with coagulation dysfunction or severe skin damage and infection (7) Pregnant or lactating women; (8) Those who have metal implants in the body and suffer from claustrophobia and other contraindications to MRI examinations; (9) Severe cranial anatomical structure asymmetry or clear lesions are found in MRI scans; (10) Moderate constipation in the past 3 months (duration > In June, or < 6 months, but the symptoms of constipation are serious, conscious of pain, conservative treatment is ineffective or poor, seriously affect life) or moderate diarrhea (watery stool, 3~5 times within 24 hours, conscious of pain or interference with daily activities); (11) Received drug treatment for cholecystitis, digestive tract ulcer, urinary tract infection, acute pyelonephritis, cystitis in the past 1 month; (12) Antibiotics have been used in the past 3 months for 3 days or more; (13) Those who participated in other clinical trials within the past 3 months or at the same time.

Design outcomes

Primary

MeasureTime frame
St. George's Respiratory Questionnaire;

Secondary

MeasureTime frame
PSQI;modified Medical research council;Self-rating depression scale;Pulmonary function test;Borg dyspnea score before and after 6MWT;Self-rating anxiety scale;The number of patients with acute exacerbation of COPD and the proportion of occurrence times;SF-36 Quality of Life Score;Walking distance for the 6-minute walk test;COPD assessment test;

Countries

China

Contacts

Public ContactLing Zhao

Hospital of Chengdu University of Traditional Chinese Medicine / Chengdu University of Traditional Chinese Medicine

zhaoling@cdutcm.edu.cn13568801429

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026